Peter W. PENG, Author at MediaMedic

Interview with Dr. Girard Deciphers at ELCC 2023

By Peter W. PENG 2023.10.24

The 2023 European Lung Cancer Congress (ELCC) was held from March 29th to April 1st, in a combined online and offline format in Copenhagen, Denmark. Professor Nicolas Girard from the Curie Institute in Paris, France, presented the 3-year data update (Abstract 84O) of the CheckMate 816 study on neoadjuvant immune combined with chemotherapy in the Proffered Paper 2 session. In an interview with Oncology Frontier he further discussed the significant research data released at ELCC 2023, the status of dual immune checkpoint inhibitor regimens in the treatment of driver gene-negative non-small cell lung cancer (NSCLC), and the treatment of EGFR exon 20 insertion mutations (ex20ins) subtype.

Interview with Minggui Wang at ECCMID 2023

By Peter W. PENG 2023.10.23

The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) recently took place in Copenhagen, Denmark, drawing attention as one of the first major in-person events since the easing of the COVID-19 pandemic. The event, a hallmark in the world of infectious diseases and clinical microbiology, attracted numerous participants, among whom was Dr. Minggui Wang, the director of the Institute of Antibiotics, Huashan Hospital, Fudan University. Dr. Wang shared insights on the advances and experiences at the conference, with a particular focus on fungal infections.

Dr. Michelle Seif: CAR-T Therapy’s Potential in Treating Fungal Infections丨ECCMID 2023

By Peter W. PENG 2023.10.23

At the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023), the prospect of utilizing Chimeric Antigen Receptor T-cells (CAR-T) for medical treatments has emerged as a promising avenue, especially in the realm of infectious diseases. Notably, Dr. Michelle Seif from the University Hospital Würzburg, Germany, has presented new findings that expand upon the potential use of CAR-T therapy in fungal infections.

Dr. José Luis Del Pozo: The Fight Against Gram-Positive Bacterial Infections丨ECCMID 2023

By Peter W. PENG 2023.10.23

In an era where antibiotic-resistant infections like MRSA are on the rise, healthcare professionals are constantly in search of potent drugs to combat these pathogens. The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) presented an opportunity to explore advancements in this area. One of the notable voices at this congress was Dr. José Luis Del Pozo from the University of Navarra. Infectious Disease Frontline had a chance to sit down with him for a comprehensive discussion.

Antimicrobial Susceptibility Testing: Insights from EUCAST Pioneer, Dr. Gunnar Kahlmeter丨ECCMID 2023

By Peter W. PENG 2023.10.23

Antimicrobial susceptibility testing (AST) is critical in modern medicine, helping doctors determine which antibiotics are most likely to be effective against particular bacterial infections. Across the globe, standards for AST primarily revolve around the European EUCAST and the American CLSI. Dr. Gunnar Kahlmeter, one of the main architects of EUCAST, offers unique insights into the past, present, and future of AST.

Dr. Anne J. Gonzales-Luna: Progress in Pediatric Clostridioides difficile Infection丨ECCMID 2023a

By Peter W. PENG 2023.10.23

Clostridioides difficile, a primary cause of antibiotic-associated diarrhea, presents a spectrum of clinical manifestations. While less prevalent in children than adults, the incidence of pediatric Clostridioides difficile infection (CDI) is on the rise. The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) dedicated a session to shed light on this pressing issue, with Dr. Anne J. Gonzales-Luna from the University of Houston College of Pharmacy offering her expertise.

Youth Forum of APACC 2023 | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

By Peter W. PENG 2023.10.23

Hello everyone, I'm Xiaosheng Liu , a graduate student from Professor Taisheng Li's team of Peking Union Medical College Hospital, China. My primary research focus is on the mechanisms underlying immunological non-response in HIV/AIDS patients after long-term antiviral therapy and the development of therapeutic drugs for this condition. I'm delighted to participate in this year's APACC conference (2023) and present two poster studies conducted by our team at the conference. APACC is the most cutting-edge and top academic conference in the Asia-Pacific region for HIV/AIDS, and I hope to broaden my knowledge in various aspects through this conference.

Dr. Reena Rajasuriar: Eliminating Regional Disparities to Achieve the 2030 End of HIV Epidemic

By Peter W. PENG 2023.10.22

Co-President of APACC 2023, Chief Researcher at the Center of Excellence for HIV/AIDS Research (CERiA) at the University of Malaya, Associate Professor at the Faculty of Medicine, University of Malaya, Research Fellow at the Peter Doherty Institute for Infection and Immunity, University of Melbourne. She is primarily responsible for the University of Malaya's HIV Immunology Translational Research Program, with her current research focus on the immunopathogenic mechanisms of aging in HIV/AIDS patients and their impact on patient health.

Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

By Peter W. PENG 2023.10.22

Honorary Dr. at the Amsterdam University Medical Center, University of Amsterdam, former President of the European AIDS Clinical Society (EACS) (2008-2012), former Regional Director for Europe and Central Asia on the Governing Council of the International AIDS Society (IAS) (2006-2014), Co-Chair of the 22nd International AIDS Conference (AIDS 2018), Director of the Netherlands HIV Monitoring Foundation, member of the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NAID) HIV Vaccine Data and Safety Monitoring Board, and member of various committees including CROI, EACS, and HIV Glasgow.

Dr. Linghua Li: Breakthrough on Hepatitis B Cure in HIV/HBV Co-Infected Patients

By Peter W. PENG 2023.10.22

The 8th Asia-Pacific AIDS and Co-infection Conference (APACC 2023) was held in Singapore from June 8 to 10, 2023. During this conference, an oral presentation (Abstract #9) conducted by Dr. Linghua Li's team from the Eighth Affiliated Hospital, Guangzhou Medical University, China, attracted significant attention. Dr. Li 's team, based on the latest findings from a large cohort study, revealed that the hepatitis B surface antigen (HBsAg) clearance rate in HIV/HBV co-infected individuals who received long-term combination antiretroviral therapy (cART) could reach 8.1%. Furthermore, the research results unveiled that the main influencing factors for HBsAg clearance in HIV/HBV co-infected individuals included low baseline HBsAg levels, HBV genotype B, and a more than two-fold increase in ALT within six months of treatment.